Table 2 Demographics and procedure characteristics reported in 11 trials of Gliadel wafers combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma

Aoki et al. [27]

Resection + Gliadel wafer + RT/TMZ

16

16

50 (21–63)

50.0 %

87.5 % >80

Mean 91.9 %

No

≤8

Bock et al. [28]

Resection + Gliadel wafer + RT/TMZ

44

44

57 (28–74)

63.6 %

81 ± 15.3

86 % total

No

7.3 ± 1.3

Burri et al. [29]

Resection + Gliadel wafer + early TMZ (day 4) + RT/TMZ

46

46

56 (19–73)

60.9 %

80

70 % total

Yes, performed on 22 pts

8

Duntze et al. [30]

Resection + Gliadel wafer + RT/TMZ

92

65

58 (34–76)

69.6 %

Median 80

86 % >90 %

No

6.5

McGirt et al. [31]

(1) Resection + Gliadel wafer + RT/TMZ

33

33

57 (50–81)

60.0 %

80

77 % total

No

8

(2) Resection + Gliadel wafer + RT

78

NA

NA

(3) Resection/biopsy + RT/TMZ

45

(18–70)

NA

Menei et al. [32]

(1) Resection + Gliadel wafer + RT/TMZ

43

43

60 (18–80)

58.1 %

Median 80

84.3 % >90 %

No

8

(2) Resection + Gliadel wafer + other regimens

40

Miglierini et al. [33]

Resection + Gliadel wafer + RT/TMZ

24

22

Mean 60.25

Median 63

5 pts >70

70.8 %

75 % PS 0–1

50 % total

No

8

Noel et al. [34]

(1) Resection + Gliadel wafer + RT/TMZ

28

28

61 (17–82)

53.6 %

92.8 % ≥80

35.7 % total

Yes

8

(2) Resection/biopsy + RT/TMZ

37

61 (17–82)

40.5 %

81.1 % ≥80

24.3 % total

Pan et al. [35]

Resection + Gliadel wafer + RT/TMZ

21

21

60 (48–83)

66.7 %

Median 80

67 % total

No

8

Pavlov et al. [36]

Resection + Gliadel wafer + RT/TMZ

83

61

59.9 (21–78)

60.2 %

94 % ≥70

49.1 % total

No

7.1 (3–13)

Salvati et al. [37]

Resection + Gliadel wafer + RT/TMZ

32

32

Median 58.5 (35–72)

50.0 %

Mean 80.6

100 % total

No

8 (5–10)